PF-Atlas › Clinical Trials › NCT05712538

Safety, Tolerability, and Pharmacokinetics of ARCT-032 in Healthy Adult Subjects and Adults With Cystic Fibrosis.

ARCT-032 · Phase 1

Registry ID

NCT05712538

Phase

Phase 1

Status

Completed

Drug / intervention

ARCT-032

Sponsor

Arcturus Therapeutics, Inc.

Start

2023-02-15

About this trial

ARCT-032 is evaluated in NCT05712538, a Phase 1 idiopathic pulmonary fibrosis study sponsored by Arcturus Therapeutics, Inc.. Current status: Completed.

View NCT05712538 on ClinicalTrials.gov →

Explore related

All ARCT-032 trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT05712538 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.